Sustained biochemical control in patients with acromegaly treated with lanreotide depot 120 mg administered every 4 weeks, or an extended dosing interval of 6 or 8 weeks: a pharmacokinetic approach
Research and Reports in Endocrine Disorders · 2012
DOI: 10.2147/rred.s38149 ↗Kurz gefasst
Fachartikel in der Zeitschrift Research and Reports in Endocrine Disorders, 2012. Verfasst von Edda Gomez-Panzani und 4 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Gomez-Panzani, E., Chang, Ramis, J., Landolfi, & Bakker, B. (2012). Sustained biochemical control in patients with acromegaly treated with lanreotide depot 120 mg administered every 4 weeks, or an extended dosing interval of 6 or 8 weeks: a pharmacokinetic approach. Research and Reports in Endocrine Disorders. https://doi.org/10.2147/rred.s38149
Vancouver
Gomez-Panzani E, Chang, Ramis J, Landolfi, Bakker B. Sustained biochemical control in patients with acromegaly treated with lanreotide depot 120 mg administered every 4 weeks, or an extended dosing interval of 6 or 8 weeks: a pharmacokinetic approach. Research and Reports in Endocrine Disorders. 2012. doi:10.2147/rred.s38149
BibTeX
@article{GomezPanzani2012,
author = {Gomez-Panzani, Edda and Chang and Ramis, Joaquim and Landolfi and Bakker, Bert},
title = {Sustained biochemical control in patients with acromegaly treated with lanreotide depot 120 mg administered every 4 weeks, or an extended dosing interval of 6 or 8 weeks: a pharmacokinetic approach},
journal = {Research and Reports in Endocrine Disorders},
year = {2012},
doi = {10.2147/rred.s38149}
}
EUVIMED